FindTrial
Sign In

Salvianolic acid A inhibits the activation and aggregation of platelets in patients with acute coronary syndrome

Salvianolic acid A inhibits the activation and aggregation of platelets in patients with acute coronary syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2024000668
Enrollment
Unknown
Registered
2024-11-06
Start date
2022-10-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute coronary syndrome

Interventions

Salvianolic acid Group A:0.1 mg/ml was selected as the effective concentration to evaluate the inhibitory effect of salvianolic acid A on platelets. SAA group was added with 10 µL salvianolic acid A s
Control group:Add 10 µL of 5% PBS solution

Sponsors

Lishui Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-80 years old; (2) Agree to sign informed consent; (3) Diagnosed with ACS; (4) Willing to participate in this study.

Exclusion criteria

Exclusion criteria: a. Hemodynamic instability; b. Severe impairment of liver and kidney function malignant tumor HIV/AIDS; c. History of blood system diseases history of diagnosed bleeding diseases bleeding tendency (such as gastrointestinal bleeding cerebral hemorrhage etc.); d. Abnormal platelet-related indexes; e. Refusal to sign informed consent.

Design outcomes

Primary

MeasureTime frame
Platelet aggregation rate;Platelet activation rate;—

Secondary

MeasureTime frame
Clinical Data Characteristics;—

Countries

China

Contacts

Public ContactChunlai Zeng

Lishui Central Hospital

zengchunlai788710@lsu.edu.cn18957098710

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026